PVLAHIGH SIGNALFINANCIAL10-K

PVLA experienced substantial cash burn with stockholders' equity declining by over half while revenue grew notably, indicating significant operational challenges despite top-line expansion.

The dramatic decline in stockholders' equity from $62.6M to $28.0M signals severe cash consumption that outpaced the company's revenue growth, raising concerns about the sustainability of current operations. The company's regulatory progress, including upgrades from Fast Track to Breakthrough Therapy Designation, provides some positive momentum but may not offset the immediate financial pressures facing this clinical-stage biotechnology company.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

PVLA's financial position deteriorated markedly over the period, with stockholders' equity cut by more than half and total assets declining by nearly one-third as cash reserves dropped from $83.6M to $58.0M. Despite revenue growing substantially, the company's cash burn significantly outpaced top-line expansion, while total liabilities increased by 23.2%. The combination of reduced capital expenditure and substantial cash consumption suggests PVLA is managing resources carefully while facing mounting financial pressures in advancing its clinical programs.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-83.6%
$1.0M→$171K

Capex reduced 83.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Revenue
P&L
+65.3%
$25.9M→$42.8M

Strong top-line growth of 65.3% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-55.3%
$62.6M→$28.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-33.1%
$88.2M→$59.0M

Current assets declined 33.1% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-32.5%
$88.2M→$59.6M

Total assets contracted 32.5% — asset sales, write-downs, or balance sheet optimization underway.

Cash & Equivalents
Balance Sheet
-30.6%
$83.6M→$58.0M

Cash declined 30.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+23.2%
$25.6M→$31.6M

Liabilities increased 23.2% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
The rare skin diseases and vascular malformations we are currently targeting have no U.S.
Our lead product candidates are based on our QTORIN platform and we are consequentially highly dependent on the successful development of this novel and unproven technology.
Orphan Drug Designation has been granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformation (microcystic LM), but we may be unable to obtain such designation for other product candidates or to realize the benefits of Orphan Drug Designation, including potential marketing exclusivity, even if such designation is obtained.
Our development and commercialization strategy for our product candidates depends, in part, on published scientific literature and the FDA s prior findings regarding the safety and efficacy of rapamycin, pitavastatin, and other planned or future product candidates.
Breakthrough Therapy Designation has been granted for QTORIN rapamycin for the treatment of microcystic LM but we may never be able to realize the benefits of such designation for QTORIN rapamycin or any other indications or future product candidates, if granted, and such designation may not lead to a faster development, regulatory review or approval process or increase the likelihood that our product candidates will receive marketing approval.
We intend to leverage our versatile QTORIN platform to minimize the challenges and timelines typically associated with generating novel topical product candidates.
The QTORIN platform is specifically designed to reproducibly generate novel topical product candidates that penetrate the deep layers of the skin to locally treat a broad spectrum of rare skin diseases and vascular malformations.
In February 2026, we announced positive topline results from SELVA, a Phase 3, single-arm, baseline-controlled study, which evaluated the safety and efficacy of QTORIN rapamycin for the treatment of microcystic LMs in patients 3 years and older.
The study met the pre-specified primary endpoint, the mLM Investigator Global Assessment ( mLM-IGA ), with a +2.13 (p 0.001) improvement.
The study also met its pre-specified key secondary and all four additional secondary endpoints with statistical significance (all p 0.001).
REMOVED
The rare genetic skin diseases we are currently targeting have no U.S.
Our lead product candidates are based on our QTORIN platform, which is highly dependent on the successful development of this novel and unproven technology.
We may be unable to obtain Orphan Drug Designation for certain of our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved.
Our development and commercialization strategy for our product candidates depends, in part, on published scientific literature and the FDA s prior findings regarding the safety and efficacy of rapamycin.
Fast Track Designation granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformation (microcystic LM) and, if granted by the FDA, for any of our other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.
We intend to leverage our versatile QTORIN platform to treat these patients.
The QTORIN platform is designed to generate potential new therapies that penetrate the deep layers of the skin to locally treat a broad spectrum of rare genetic skin diseases.
We currently have two ongoing clinical trials: (i) SELVA, a Phase 3, single-arm, baseline-controlled study evaluating the safety and efficacy of QTORIN rapamycin for the treatment of microcystic LMs in patients 3 years and older and (ii) TOIVA, a Phase 2, single-arm, open-label, baseline-controlled study evaluating the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs in patients 6 years and older.
In the third quarter of 2024, we initiated SELVA, a 24-week, Phase 3, single-arm, baseline-controlled clinical trial of QTORIN rapamycin administered once daily for the treatment of microcystic LMs.
The primary efficacy endpoint is the change from baseline in the overall microcystic LM Investigator Global Assessment ( mLM-IGA ), a 7-point clinician rated change scale, at week 24.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →